title: Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia.
abstract: Aggressive natural killer cell leukemia (ANKL) is a highly aggressive lymphoproliferative disease. An appropriate therapeutic strategy for ANKL remains to be established, but a few case reports have suggested that allogeneic hematopoietic stem cell transplantation (allo-HCT) can be curative. Here, we report a young woman with ANKL showing central nervous system (CNS) invasion, who has been in complete remission for more than a year after allo-HCT following two courses of intravenous chemotherapy and several rounds of intrathecal chemotherapy. Intensive remission induction chemotherapy followed by conventional myeloablative allo-HCT is a promising approach for long-term remission in cases of this aggressive malignancy.
authors.affiliation: Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ichikawa
authors.forename: Noriko
authors.initials: N
authors.lastname: Fukuhara
authors.forename: Joji
authors.initials: J
authors.lastname: Yamamoto
authors.forename: Makiko
authors.initials: M
authors.lastname: Suzuki
authors.forename: Shinji
authors.initials: S
authors.lastname: Nakajima
authors.forename: Yoko
authors.initials: Y
authors.lastname: Okitsu
authors.forename: Katsura
authors.initials: K
authors.lastname: Kohata
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Onishi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ishizawa
authors.forename: Junichi
authors.initials: J
authors.lastname: Kameoka
authors.forename: Hideo
authors.initials: H
authors.lastname: Harigae
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D001921:Brain / Q000473:pathology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections / Q000821:virology; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007278:Injections, Spinal; D054066:Leukemia, Large Granular Lymphocytic / Q000188:drug therapy / Q000601:surgery* / Q000821:virology; D017254:Leukemic Infiltration; D008727:Methotrexate / Q000008:administration & dosage; D019653:Myeloablative Agonists / Q000627:therapeutic use; D036102:Peripheral Blood Stem Cell Transplantation; D011241:Prednisone / Q000008:administration & dosage; D011859:Radiography; D012074:Remission Induction; D013345:Subarachnoid Hemorrhage / Q000000981:diagnostic imaging / Q000209:etiology; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D019653:Myeloablative Agonists; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate